David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Harvard-MIT Health Sciences and Technology Division, Harvard Medical School, Boston, MA, USA.
FEBS Lett. 2020 Feb;594(4):646-664. doi: 10.1002/1873-3468.13648. Epub 2019 Nov 16.
Mammalian pyruvate kinase catalyzes the final step of glycolysis, and its M2 isoform (PKM2) is widely expressed in proliferative tissues. Mutations in PKM2 are found in some human cancers; however, the effects of these mutations on enzyme activity and regulation are unknown. Here, we characterized five cancer-associated PKM2 mutations, occurring at various locations on the enzyme, with respect to substrate kinetics and activation by the allosteric activator fructose-1,6-bisphosphate (FBP). The mutants exhibit reduced maximal velocity, reduced substrate affinity, and/or altered activation by FBP. The kinetic parameters of five additional PKM2 mutants that have been used to study enzyme function or regulation also demonstrate the deleterious effects of mutations on PKM2 function. Our findings indicate that PKM2 is sensitive to many amino acid changes and support the hypothesis that decreased PKM2 activity is selected for in rapidly proliferating cells.
哺乳动物丙酮酸激酶催化糖酵解的最后一步,其 M2 同工酶(PKM2)广泛表达于增殖组织中。PKM2 的突变存在于一些人类癌症中;然而,这些突变对酶活性和调节的影响尚不清楚。在这里,我们对发生在酶的不同位置的五个与癌症相关的 PKM2 突变进行了研究,以了解它们对底物动力学和变构激活剂果糖-1,6-二磷酸(FBP)的影响。这些突变体表现出降低的最大速度、降低的底物亲和力和/或改变的 FBP 激活作用。另外五个用于研究酶功能或调节的 PKM2 突变体的动力学参数也表明了突变对 PKM2 功能的有害影响。我们的研究结果表明,PKM2 对许多氨基酸变化敏感,并支持了在快速增殖细胞中选择降低的 PKM2 活性的假说。